BR112022022604A2 - Vírus recombinante da doença de newcastle expressando proteína spike sars-cov-2 e seus usos - Google Patents

Vírus recombinante da doença de newcastle expressando proteína spike sars-cov-2 e seus usos

Info

Publication number
BR112022022604A2
BR112022022604A2 BR112022022604A BR112022022604A BR112022022604A2 BR 112022022604 A2 BR112022022604 A2 BR 112022022604A2 BR 112022022604 A BR112022022604 A BR 112022022604A BR 112022022604 A BR112022022604 A BR 112022022604A BR 112022022604 A2 BR112022022604 A2 BR 112022022604A2
Authority
BR
Brazil
Prior art keywords
cov
protein
sars
newcastle disease
spike protein
Prior art date
Application number
BR112022022604A
Other languages
English (en)
Portuguese (pt)
Inventor
Sun Weina
Krammer Florian
Garcia-Sastre Adolfo
Palese Peter
Original Assignee
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/022848 external-priority patent/WO2021194826A2/en
Application filed by Icahn School Med Mount Sinai filed Critical Icahn School Med Mount Sinai
Publication of BR112022022604A2 publication Critical patent/BR112022022604A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112022022604A 2020-05-07 2021-05-06 Vírus recombinante da doença de newcastle expressando proteína spike sars-cov-2 e seus usos BR112022022604A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063021677P 2020-05-07 2020-05-07
US202063051858P 2020-07-14 2020-07-14
US202063057267P 2020-07-27 2020-07-27
US202063058435P 2020-07-29 2020-07-29
US202063059924P 2020-07-31 2020-07-31
PCT/US2021/022848 WO2021194826A2 (en) 2020-03-24 2021-03-17 Recombinant sars-cov-2 spike protein and uses thereof
PCT/US2021/031110 WO2021226348A2 (en) 2020-05-07 2021-05-06 Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof

Publications (1)

Publication Number Publication Date
BR112022022604A2 true BR112022022604A2 (pt) 2023-03-28

Family

ID=78468787

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022604A BR112022022604A2 (pt) 2020-05-07 2021-05-06 Vírus recombinante da doença de newcastle expressando proteína spike sars-cov-2 e seus usos

Country Status (7)

Country Link
US (1) US20230310583A1 (https=)
EP (1) EP4146674A4 (https=)
JP (1) JP2023524990A (https=)
BR (1) BR112022022604A2 (https=)
CA (1) CA3178875A1 (https=)
MX (1) MX2022013934A (https=)
WO (1) WO2021226348A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229270A1 (es) * 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
CN113881704B (zh) * 2021-11-17 2024-02-13 浙江迪福润丝生物科技有限公司 一种包含新型冠状病毒双抗原靶标序列组合的重组新城疫病毒载体及相应疫苗株和疫苗
CN114196701B (zh) * 2021-11-17 2023-10-10 浙江迪福润丝生物科技有限公司 一种sars-cov-2的二价重组新城疫病毒载体及相应疫苗株和制备方法
CN117247463A (zh) * 2021-12-16 2023-12-19 浙江迪福润丝生物科技有限公司 一种展示新冠病毒s蛋白的融合蛋白和重组病毒粒子及其应用
KR20240137110A (ko) * 2022-02-02 2024-09-19 워싱턴 유니버시티 오미크론 코로나바이러스 백신 구조체 및 이를 제조하고 사용하는 방법
JP2025509352A (ja) * 2022-03-10 2025-04-11 アイカーン スクール オブ メディスン アット マウント サイナイ Ｃｏｖｉｄ－１９の予防に使用するための組み換え型ニューカッスル病ウイルスおよび免疫原性組成物
US20250228929A1 (en) * 2022-04-03 2025-07-17 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
WO2024174012A1 (pt) * 2023-02-24 2024-08-29 Instituto Butantan Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101492643B1 (ko) * 2005-12-02 2015-02-12 이칸 스쿨 오브 메디슨 엣 마운트 시나이 비-천연 표면 단백질을 제시하는 키메라 바이러스 및 그의용도
MX2019011599A (es) * 2017-03-30 2019-12-19 Univ Queensland Moleculas quimericas y usos de las mismas.
US20190382450A1 (en) * 2018-06-18 2019-12-19 University Of Maryland, College Park Newcastle disease virus-based vectored vaccine

Also Published As

Publication number Publication date
MX2022013934A (es) 2023-02-22
WO2021226348A3 (en) 2021-12-09
CA3178875A1 (en) 2021-11-11
JP2023524990A (ja) 2023-06-14
EP4146674A2 (en) 2023-03-15
EP4146674A4 (en) 2024-07-10
US20230310583A1 (en) 2023-10-05
WO2021226348A2 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
BR112022022604A2 (pt) Vírus recombinante da doença de newcastle expressando proteína spike sars-cov-2 e seus usos
US12297237B2 (en) Mutated glycoprotein of vesicular stomatitis virus
von Messling et al. The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity
Nogales et al. Influenza A virus attenuation by codon deoptimization of the NS gene for vaccine development
Song et al. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein
Robison et al. The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly
Heaton et al. In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies
Aspehaug et al. Characterization of the infectious salmon anemia virus fusion protein
Bertolotti-Ciarlet et al. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins
Ader et al. Mechanism for active membrane fusion triggering by morbillivirus attachment protein
Tahara et al. Altered interaction of the matrix protein with the cytoplasmic tail of hemagglutinin modulates measles virus growth by affecting virus assembly and cell-cell fusion
JP2024161055A (ja) 安定化されたｎａを有する組換えインフルエンザウイルス
Samal et al. Coordinate deletion of N-glycans from the heptad repeats of the fusion F protein of Newcastle disease virus yields a hyperfusogenic virus with increased replication, virulence, and immunogenicity
BR112022019949A2 (pt) Vacina com base em vetor de poxvírus atenuado para proteção contra covid-19
AU2011351380A1 (en) Expression systems
JP5432703B2 (ja) 組み換えモノネガウイルス目ウイルスベクター
Wessel et al. Human monoclonal antibodies against NS1 protein protect against lethal West Nile virus infection
US12303560B2 (en) Recombinant bovine immunodeficiency virus-like particles comprising an influenza HA transmembrane domain and C-terminus
US20130071429A1 (en) Bunyavirus vaccine
CN115003328A (zh) 重组神经氨酸酶及其用途
Zhang et al. Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate
WO2006009011A1 (ja) コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
AU2017405996A1 (en) Chimeric insect-specific flaviviruses
AR124461A1 (es) VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2
US20250041398A1 (en) A therapeutic against crimean-congo hemorrhagic fever virus